Feb 13 (Reuters) - Allogene Therapeutics Inc ALLO.O:
ALLOGENE THERAPEUTICS ANNOUNCES PUBLICATION OF DURABLE RESPONSE DATA FROM PHASE 1 ALPHA/ALPHA2 TRIALS OF THE ALLOGENEIC CAR T CEMACABTAGENE ANSEGEDLEUCEL/ALLO-501 IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY
ALLOGENE THERAPEUTICS INC - CEMA-CEL ACHIEVES ORR OF 58% AND CR OF 42% IN STUDY
Source text: ID:nGNX75ZxGV
Further company coverage: ALLO.O